Announcement • May 28
Ab&B Bio-Tech CO., LTD. JS Appoints Lui Mei Ka as Independent Non-Executive Director and Member of the Audit Committee, with Effect from May 27, 2026 Ab&B Bio-Tech CO., LTD. JS at its first extraordinary general meeting of 2026 held on May 27, 2026, Subject to the passing of the proposed resolution on the amendments to the Articles of Association, the proposed resolution on the appointment of Ms. LUI Mei Ka (‘Ms. Lui’) as an independent non-executive Director of the Company was duly passed at the EGM. According to the Articles of Association, Ms. Lui has been elected as an independent non-executive Director of the second session of the Board. Further to the appointment of Ms. Lui, the Board is also announce that with effect from the close of the EGM on May 27, 2026, Ms. Lui has been appointed as a member of the Audit Committee of the Board. New Risk • Mar 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥229m free cash flow). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Announcement • Jan 31
Ab&B Bio-Tech Co., Ltd. Announces Approval of Application for Trivalent Subunit Influenza Vaccine by the National Medical Products Administration of the People's Republic of China The board of directors of Ab&B Bio-Tech CO., LTD. JS announced that, the National Medical Products Administration of the People's Republic of China (the NMPA) has approved the new drug application for the Group's trivalent subunit influenza vaccine for all age groups. This was the first and only trivalent sub unit influenza vaccine approved in China for all age groups at full dosage level as of the date of this announcement. This product is a significant upgrade from the traditional split-virion vaccines, offering comprehensive protection, high antigen purity and low risks of adverse reactions. 
